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Abstract
Background: The seroprevalence of IgG antibodies of Streptococcus gallolyticus subspecies gallolyticus, CIP
105428, was evaluated to investigate the controversial association of S. gallolyticus with colorectal
carcinoma and adenoma in attempt to investigate the nature of such association if any, by exploring the
mRNA expression of NF-κB and IL-8. Moreover, the serological behavior of S. gallolyticus IgG antibodies
was compared to that of an indicator bacterium of bowel, Bacteroides fragilis.
Methods: ELISA was used to measure IgG antibodies of S. gallolyticus and B. fragilis in sera of 50 colorectal
cancer, 14 colorectal adenoma patients, 30 age- and sex- matched apparently healthy volunteers (HV) and
30 age- and sex- matched colonoscopically-proven tumor-free control subjects. NF-κB and IL-8 mRNA
expression was evaluated in tumorous and non-tumorous tissue sections of carcinoma and adenoma
patients in comparison with that of control subjects by using in situ hybridization assay.
Results: Colorectal cancer and adenoma patients were associated with higher levels of serum S. gallolyticus
IgG antibodies in comparison with HV and control subjects (P < 0.05) while no similar association was
found with serum IgG antibodies of B. fragilis (P > 0.05). ELISA cutoff value for the seropositivity of S.
gallolyticus IgG was calculated from tumor-free control group. The expression of NF-κB mRNA was higher
in tumorous than non-tumorous tissue sections of adenoma and carcinoma, higher in carcinoma/adenoma
sections than in control subjects, higher in tumorous sections of carcinoma than in adenoma patients, and
higher in S. gallolyticus IgG seropositive than in seronegative groups in both tumorous and non-tumorous
sections (P < 0.05). IL-8 mRNA expression in tumorous sections of adenoma and carcinoma was higher
than in non-tumorous sections, higher in carcinoma/adenoma than in control subjects, and higher in S.
gallolyticus IgG seropositive than in seronegative groups in tumorous rather than non-tumorous sections
(P < 0.05).
Conclusion: S. gallolyticus most likely plays an essential role in the oncogenic progression of normal
colorectal mucosa to adenoma and to CRC. This promoting/propagating role of S. gallolyticus might take
place by utilizing certain inflammatory, anti-apoptotic, and angiogenic factors of transformation including
NF-κB and IL-8.
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Colorectal cancer (CRC) is the fourth commonest form of
cancer occurring worldwide. The number of new cases of
colorectal cancer has been increasing rapidly since 1975
[1]. Several studies have associated bacterial infections to
carcinogenesis [2,3]. CRC was associated with Streptococ-
cus bovis (S. bovis); the incidence of the association of
colonic neoplasia with S. bovis has been determined as
18% to 62% [4,5]. Colonic neoplasia may arise years after
the presentation of the condition of bacteremia or infec-
tious endocarditis of S. bovis [5,6].
Prior to the description of S. gallolyticus, it was reported
that among S. bovis biotypes identified by the API Rapid
Strep system and cellular fatty acid content, biotype I was
more likely than biotype II to be associated with both
endocarditis and malignant or premalignant colonic
lesion [7]. Following the description of S. gallolyticus,
Devriese team showed that the bacterial isolates, which
were studied previously and derived from patients with
endocarditis and associated with colonic cancers and
identified by conventional techniques as S. bovis, were in
fact S. gallolyticus [8]. They suggested that S. gallolyticus is
more likely to be involved in human infections than S.
bovis and most of S. gallolyticus strains belong to the so-
called S. bovis biotype I and a few belong to S. bovis bio-
type II/2. Recently S. gallolyticus subspecies gallolyticus has
become the most implicated agent in the association with
CRC as Schlegel et al. stated that most of the human
strains isolated from blood or feces were Streptococcus gal-
lolyticus which is often responsible for endocarditis cases
associated with a colonic cancer [9].
After the new species, S. gallolyticus, was assigned, there
has been no specific serological study done for the associ-
ation between S. gallolyticus and CRC or colorectal ade-
noma. Therefore, we conducted a serological investigation
of S. gallolyticus IgG antibodies in CRC and colorectal ade-
noma patients in comparison with normal individuals. To
keep the scientific fidelity, we accompanied another intes-
tinal bacterium, namely Bacteroides fragilis (B. fragilis),
strain ATCC 25285. B. fragilis is one of the most dominant
bacteria in the normal flora of humans' large intestine and
present in bowel at incidence of 100% [10]. B. fragilis was
selected for this comparison because B. fragilis is confined
to the bowel and isolated from the blood circulation by an
integral mucosal barrier; any breach, say degenerative
lesion or ulceration, in the mucosal barrier of the bowel
leads to showering of huge amount of B. fragilis into
blood circulation which results in a vigorous immune
response [11]. Although no quantitative comparison was
aimed between the seroprevalence of B. fragilis and S. gal-
lolyticus, as they are of different species, we intended to
compare the behavior or trend of the seroprevalence of B.
fragilis lipopolysaccharides (LPS) IgG antibodies among
CRC, adenoma and normal subjects to that of our target
bacteria, S. gallolyticus cell wall antigens IgG antibodies.
The reason behind that was to assess whether the associa-
tion of S. gallolyticus with CRC and adenoma is specific or
other bowel bacteria are associated too through a non-
specific entry of bowel bacteria into blood circulation via
tumor lesion. In addition, LPS of B. fragilis is a specific
antigen and not shared with other Gram negative/positive
bacteria. It was reported that no cross-reactivity between
B. fragilis LPS and LPS of other bacteria was observed and
B. fragilis LPS contains an immunodominant antigenic
determinant common to almost all B. fragilis isolates
[11,12]. Moreover, it was revealed that anti-B. fragilis IgM,
IgG, and IgA antibodies in mice and human serum were
measured reliably by using B. fragilis LPS in enzyme
immune assays [13,14].
Previous experiments by our team showed no link
between S. gallolyticus-associated CRC and a number of
tumor suppressor proteins, p53, p21, and p27 [unpub-
lished data] as these factors were found to be greatly asso-
ciated with the transformation process of colorectal
mucosa to adenoma and then to carcinoma [15]. There-
fore, in the current study, un-researched before, target
molecules, namely, nuclear factor kappa-B (NF-κB) and
interleukin-8 (IL-8) were studied in relation with S. gallo-
lyticus as well as the transformation of colorectal mucosa
to adenoma and carcinoma. Accordingly, the mRNA
expression of NF-κB, a central transcriptional factor for
inflammation [16] and IL-8, a powerful angiogenic chem-
okine which is frequently related to bacterial carcinogen-
esis e.g. H. pylori [17], were evaluated using in situ
hybridization (ISH) assay.
Methods
The population of the study
CRC patients were those who attended several Gastroen-
terology and Hepatology Centers in the state of Selangor,
Malaysia from March 2006 to December 2007, that
underwent elective surgical resection of colorectal cancer.
Adenoma patients were those who were referred to do
colonoscopy due to various reasons and resection of intes-
tinal polyps was done. Twenty seven men and 23 women
with primary colorectal adenocarcinoma were included in
this study prior to any chemotherapy. On the other hand,
seven men and seven women with colorectal adenoma
who had already undergone colonoscopical resection of
adenomatous polyps were involved in this study. The
medical history of the involved patients in this study was
evaluated; no one had history of gastrointestinal disease
or ulceration which might affect the seroprevalence of S.
gallolyticus or B. fragilis. On the other hand, 30 age- and
sex- matched control subjects were involved. They were
referred to hospitals for doing colonoscopy for various
reasons in whom normal colonic mucosa was confirmedPage 2 of 12
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trointestinal diseases and ulcerations were found. Colon-
oscopical biopsy was taken from control subjects to
compare the level of IL-8 and NFKB mRNA expression
with that in mucosal colonic tissues from patients with
adenoma and CRC. Moreover, blood samples were taken
from the control group to calculate the seropositivity cut-
off value for S. gallolyticus IgG antibodies. The resultant
cutoff value was applied on CRC and adenoma patients as
well as on age- and sex- matched 30 apparently healthy
volunteers group (HV) who agreed to do colonoscopy in
case results of ELISA would show high level of S. gallolyti-
cus IgG antibodies. HV were medically examined and their
medical records and history were reviewed and no major
or gastrointestinal illness was found. Written consents
were officially obtained from all participants in this study.
The study was carried out in the scope of Helsinki declara-
tion of ethical principles of medical research and permis-
sion was granted from the Ethics Committee of
biomedical research of University Putra Malaysia.
Sampling and processing of specimens
Samples of 3 to 5 ml of blood for serum isolation were
withdrawn from control and adenoma groups at time of
colonoscopy, from HV group after taking the medical his-
tory, and from CRC patients 2-3 days before surgery.
Regarding the histopathology, a set of steps was pursued
under the supervision of a pathologist to minimize as
could as possible the fixation-related loss of mRNA. These
steps were minimal prefixation time of 1 hour, the use of
cold 4% paraformaldehyde, cold fixation at 4°C, and
short duration of fixation, up to 5 hours [18]. It was stated
that no significant loss of nucleic acids was observed
within the first 3 days of fixation-paraffin embedding
[19]. Therefore, paraffin-embedded sections were proc-
essed for ISH examination in a period of not more than 3
days. Moreover, the scoring system used in this study did
not rely on the quantitative measurement of staining
intensity. Therefore, mRNA loss, which affects mainly the
intensity of staining, was believed to affect the results of
this study minimally. To evaluate the stringent conditions
pursued for minimizing mRNA loss, the ISH immunos-
taining was compared between 6 randomly selected paraf-
fin embedded sections and cryostat sections. Despite the
bit lower intensity of staining, the mean percentage of the
positively stained cells was not changed. Hence it was con-
firmed that no loss of mRNA took place which could
affect ISH results. Each histopathological paraffin block of
excisional biopsies of CRC patients and punch biopsies of
control subjects and adenoma patients were sectioned
into 4 um thick sections. Histopathological sections were
made from both tumorous and non-tumorous tissues for
each CRC (resection safe margins) and adenoma patient
(punch biopsy 3-4 cm away from the polyp). Hematoxy-
lin and Eosin slides were prepared and examined by a his-
topathologist for confirming the histopathological
diagnosis, the grade of CRC, and the type and degree of
dysplasia of adenoma tissue sections.
Extraction of cell wall antigens of S. gallolyticus and LPS 
of B. fragilis
The reference strain, S. gallolyticus subspecies gallolyticus
CIP 105428 (Insitut de Louis Pasteur, France) was used.
The extraction of cell wall antigens of S. gallolyticus was
conducted by using the lysozyme method. Sufficient
amount of the cultured reference bacteria in Columbia
agar (Oxoid, UK) with 5% horse blood was obtained by
making bacterial suspension in 30 mM (pH 8) Tris buffer
(Fluka, Switzerland). The suspension was centrifuged at
3500 g for 10 minutes at 4°C. Pellet was washed 3 times
in 30 mM Tris buffer (pH 8) by centrifugation at 3500 g
for 5 minutes at 4°C. Pellet of washed bacteria was resus-
pended in a solution containing 4.75 ml of 30 mM Tris
buffer (pH 8), 3 mM magnesium chloride (Sigma, USA),
25% sucrose (Fluka, Switzerland) and 0.25 ml of lys-
ozyme (0.6 mg/ml) (Sigma, USA). The lysate solution was
incubated for 2 hours at 37°C and was then centrifuged at
3000 g for 5 minutes at 4°C. Then, the supernatant was
collected, which became the solution of cell wall antigens
of the reference strain, S. gallolyticus [20]. The concentra-
tion of cell wall antigens was measured by Biurette
method.
The extraction of B. fragilis LPS was obtained by the phe-
nol-water extraction method, followed by the phenol-
chloroform-petroleum ether extraction, as described by
[21].
ELISA
For S. gallolyticus, 96-wells microtiter plate (Sterilin, UK)
was coated with 40 μg/ml of cell wall antigen while, for B.
fragilis, the microtiter plate was coated with 10 μg/ml of
LPS extract. The concentration of coating antigens for the
studied bacteria was determined after a series of standard-
ization steps. The microtiter plates were incubated in a
humid chamber for 2 hours at 37°C and were then
washed and stored at -20°C until further use. It is note-
worthy to mention that the cell wall antigens of S. gallo-
lyticus had already been treated with 100 μl a well of 0.01
M sodium periodate (Sigma, USA) in PBS for two hours at
room temperature to destroy the common polysaccha-
rides antigen of group D. After 3 times washing, 50 μl sera
of CRC (50), adenoma (14), control subjects (30), and
healthy volunteers (30) were pipetted into microtiter
plates and incubated for 2 hours at room temperature. For
each run, two wells were dispensed with 50 μl of diluting
buffer as a negative control and two wells were dispensed
with known positive sera for either S. gallolyticus or B. fra-
gilis. After 3 rounds of washing, 50 μl/well of 1:40,000
diluted horseradish peroxidase anti-human IgG conju-Page 3 of 12
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hours at room temperature. Then, 50 μl/well of chro-
mogen-substrate OPD.2HCL (Abbott, USA) were pipetted
into wells and incubated in dark for 15 minutes at room
temperature. Optical density was read by ELISA reader
(Organic Technica, Spain) at 492 nm [22].
Calculation of the cutoff value for S. gallolyticus 
seropositivity
The cut off value is considered as the upper limit above
which all of readings are considered positive. ELISA read-
ings of control subjects (n = 30) were used to calculate the
cutoff value according to the following formula [23]:
[23] (2.462): taken from the table of student's t-test under
the P = 0.01 for the 29 degrees of freedom.
The cutoff value was used to demarcate between the S. gal-
lolyticus- seropositive and seronegative subjects in the
participants of this study other than control group,
namely CRC, adenoma, and HV groups
In situ hybridization assay
For each run of ISH, one negative control tissue section
(diluting buffer instead of probes), one positive tissue sec-
tion (already tested as strongly positive), and one endog-
enous positive probe control were used. Biotinylated long
DNA probe for human NF-κB mRNA and human IL-8
mRNA were used (Maximbio, USA). The used procedure
was according to "DNA probe Hybridization/Detection
System - in situ Kit" (Maximbio, USA).
Slides were baked overnight at 70°C and deparaffinized
in xylene (Merck, Germany) and descending grades of eth-
anol (Merck, Germany) starting from 100%. Freshly
diluted 1× proteinase K (Sigma, USA) solution was
applied for 15 min at 37°C. The working solutions used
for probes were 10% v/v for NF-κB and 7% v/v for IL-8
mRNA. Ten μl of the working cDNA probe was added
onto each slide. Slides were incubated in a humid cham-
ber overnight at 37°C. Next day after washing slides,
RNase A (Maximbio, USA) was added for 30 min to abol-
ish any unbound RNA. Slides were then washed three
times with a pre-warmed protein block for 3 minutes at
37°C. One to two drops of alkaline phosphatase-strepta-
vidin conjugate (Abbott, USA) were added onto tissue sec-
tions for 1.5 hour at 37°C. Then, 1-2 drops of NBT/BCIP
(Abbott, USA) substrate were placed on tissue sections at
37°C until color was developed. Dark blue colored pre-
cipitate was seen in positive cells. Slides were counter-
stained by nuclear fast red, dehydrated by graded
alcohols, and mounted with a permanent-mounting DPX
medium.
Staining analysis
The scoring systems for in situ hybridization staining of
NF-κB and IL-8 mRNA calculate the percentage of the
glandular mucosal (adeno) cells, which were stained with
nuclear blue/black color, out of total cells in 5 high power
fields. The scores for NF-κB mRNA staining are; negative
for less than 5% staining, low for 5-25% staining, inter-
mediate for 26-50% staining, and positive for more than
50% staining [24]. The scores for IL-8 mRNA are; score 1
for 1-10% staining, score 2 for 11-50% staining, and score
3 for 51-100% staining [25]. In addition, stromal cells
rather than glandular mucosal cells were observed too.
The percentage of IL-8- or NF-κB- positively stained stro-
mal cells were calculated out of total cells in 5 high power
fields. However, no specific scoring system was found for
stromal cells of human colonic tissues. Therefore, the ISH
staining percentage of stromal cells was used for compar-
isons without using a predetermined scoring system.
Statistical analysis
SPSS software version 12 for Windows (SPSS Inc., USA)
and Excel XP (Microsoft, USA) were used. To validate the
scoring systems used in this study, two sets of statistical
analyses were used. The first set, Chi square for independ-
ence and Mann-Whitney tests were used for the scoring
systems of NF-κB and IL-8 respectively. The second set, a
univariate student t test was used for direct comparisons
of the mean percentages of the positively stained cells. On
the other hand for stromal cells, only student t test for
mean percentages of the positively stained cells was used.
Pearson's correlation coefficient was used to correlate the
expression of IL-8 mRNA and NF-κB mRNA with S. gallo-
lyticus IgG antibodies in both CRC and adenoma patients.
P values less than 0.05 were considered significant.
Results
Demographic and histopathological features of CRC and 
adenoma patients
The mean age of CRC and adenoma patients was 57.08
years, ranged between 43 and 76 years, and 50.1 years,
ranged between 37 and 70 years, respectively. On the
other hand, the mean age of control and HV groups was
53.5 years, ranged between 38 and 78 years, and 52.8
years, ranged between 41 and 73 years, respectively. The
whole of CRC cases were of adenocarcinoma; 32 cases
were left-sided, 12 right-sided, and 6 at transverse colon.
Seven out of 32 left-sided CRC were located in the rectum.
Three (6%) of CRC patients were presented at B1, 5 (10%)
at B2, 5 (10%) at C1, 7 (14%) at C2, and 30 (60%) at D
stages. It was found that 30 (60%) of histological sections
of CRC patients were poorly differentiated and 20 (40%)
were mild-moderate differentiated. For adenoma, it was
found that 6 patients (43%) were of villous type, 5
(35.7%) were of tubulovillous type, and only 3 (21.4%)
were of tubular adenomatous polyps.
99 2 462% ( ) . Confidence interval cutoff value mean Standard= + ×  errormeanPage 4 of 12
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fragilis
It was found that both CRC and adenoma patients
showed significantly higher S. gallolyticus IgG antibodies
than control group. Mean ELISA readings in terms of opti-
cal density (OD) were used to measure the serum level of
S. gallolyticus IgG antibodies in both CRC (0.158 ± 0.032),
and adenoma patients (0.173 ± 0.024) which were higher
than that of HV group (0.064 ± 0.011) and control sub-
jects (0.046 ± 0.024) (P < 0.05). However, there was no
significant difference between the serum level of S. gallo-
lyticus IgG antibodies of CRC and of adenoma patients (P
> 0.05) or between the serum level of S. gallolyticus IgG
antibodies of HV group and of control group (P > 0.05)
(figure 1). On the other hand, it was found that the sero-
prevalence of B. fragilis, as an indicator for any access of
the large intestine flora into the circulation, was not
higher in CRC patients (0.166 ± 0.013) and colorectal
adenoma patients (0.178 ± 0.032) than in HV members
(0.176 ± 0.014) and control group (0.18 ± 0.02) (P >
0.05) (figure 1). In addition, there was no significant dif-
ference found in the serum level of S. gallolyticus IgG anti-
bodies among CRC patients in terms of age, sex, and
tumor site, colon versus rectum, and colon segments (P >
0.05).
The cutoff value for S. gallolyticus seroprevalence, which
was calculated from the control group, was equal to OD
value of 0.07. By applying this cutoff value on CRC, ade-
noma, and HV groups, it was found that the percentage of
seropositive subjects for S. gallolyticus IgG antibodies in
CRC group, 34 out of 50 (68%), was close to that of ade-
noma group, 11 out of 14 (78%) (P > 0.05). However,
these percentages were remarkably higher than that of HV
group, 5 out of 30 (16.66%) (P < 0.05) (figure 2). Accord-
ingly, the use of this cutoff value in ELISA for the seropos-
itivity of S. gallolyticus IgG antibodies yielded sensitivity of
68% for CRC detection and 78% for adenoma detection
and specificity of 83.33%. There was no significant differ-
ence in age and sex between seropositive and seronegative
groups of CRC, adenoma, and HV groups (P > 0.05). The
5 seropositive members of HV group were traced and 4 of
them volunteered to do colonoscopy. Three members
showed normal colonic mucosa and one showed begnine
hyperplastic polyp (0.7 cm in diameter) in the distal
colon. There was no particular history of CRC and color-
ectal adenoma in the seropositive members of HV group.
In situ hybridization expression of NF-κB mRNA and IL-8 
mRNA in CRC and adenoma patients
ISH immunostaining of mucosal (adeno) cells
The expression level of NF-κB mRNA and IL-8 mRNA (fig-
ure 3) was tested by ISH staining in tumorous versus non-
tumorous tissue sections in CRC and adenoma patients
(Table 1 and 2) and normal mucosal tissue sections from
control subjects versus tumorous and non-tumorous tis-
sue sections of CRC and adenoma patients (Table 1 and
2). In addition, the mRNA expression of NF-κB and IL-8
was tested in tumorous and non-tumorous tissue sections
of CRC versus that of adenoma patients (Tables 3 and 4)
and in CRC S. gallolyticus seropositives (CRC-Sg+ve) ver-
Serum levels of IgG antibodiesFig re 1
Serum levels of IgG antibodies. (A) The serum level of IgG antibodies of S. gallolyticus in terms of ELISA OD values. The 
high level of serum IgG antibodies of S. gallolyticus was detected in both CRC and adenoma patients which were significantly 
higher than that of HV and control group. The dashed line represents the ELISA cutoff value (OD 0.07) for the S. gallolyticus 
seropositivity measured from the tumor-free control group and applied on CRC, adenoma and HV groups. (B) The serum level 
of IgG antibodies of B. fragilis, an indicator bacterium for comparison, was not different among CRC, adenoma, HV, and control 
groups.Page 5 of 12
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(Tables 3 and 4).
At first, it was important to explore whether the mRNA
expression of NF-κB and IL-8 is intensified in tumor cells
of CRC and adenoma in comparison with normal
mucosal tissues of control subjects and the surrounding
mucosal tissue (non-tumorous) or not. It was found that
the mRNA expression of NF-κB and IL-8 in the tumorous
tissue sections of CRC and adenoma patients was higher
than in the normal mucosal tissue sections of the control
subjects and that of the corresponding non-tumorous tis-
sue sections (P < 0.05) (Table 1 and 2). This indicated a
significant association of the expression of NF-κB mRNA
and IL-8 mRNA with the tumorous tissues of both CRC
and adenoma patients rather than the surrounding non-
tumorous tissues or normal mucosal tissues. Moreover,
the non-tumorous tissue sections of CRC patients but not
adenoma patients showed higher levels of expression of
NF-κB mRNA but not IL-8 mRNA than that of normal
mucosal tissues of control subjects (Table 1). This pro-
vided evidence that NF-κB mRNA expression, unlike IL-8,
increases in the tumor-adjacent normal mucosal cells in
patients with CRC but not adenoma.
The NF-κB mRNA expression in tumorous tissue sections
of CRC patients was associated with the seropositivity of
S. gallolyticus IgG antibodies in that its expression was
higher in CRC-Sg+ve group than in CRC-Sg-ve group (P <
0.05). And NF-κB mRNA expression was higher in carci-
noma than in adenoma patients (P < 0.05) (Table 3).
However, it was found that, just like the tumorous tissue
sections, the expression of NF-κB mRNA in non-tumorous
tissue sections was higher in CRC-Sg+ve group than in
CRC-Sg-ve group (P < 0.05) but was not higher in CRC
than in adenoma (P > 0.05) (Table 3). This indicated that
high levels of NF-κB mRNA expression were associated
significantly with the seropositivity of S. gallolyticus IgG
antibodies in both tumorous cells and histologically nor-
mal adjacent cells making NF-κB as a remarkable factor
associated with the hypothesis of S. gallolyticus-associated/
triggered CRC. Moreover, NF-κB was shown to be associ-
ated with the transformation process from adenoma to
CRC. On the other hand, the level of NF-κB mRNA expres-
sion in CRC patients was not related with staging or with
tumor grade (P > 0.05). It is noteworthy to mention that
the positive expression of NF-κB was 0% in negative con-
trol tissue section, and 73% in positive control tissue sec-
tion.
For IL-8 mRNA expression, the negative control sections
showed score 0 and the positive control section showed
score 2. In tumorous tissue sections, IL-8 mRNA expres-
sion was associated with the seropositivity of S. gallolyticus
IgG antibodies in that its expression was higher in CRC-
Sg+ve group than in CRC-Sg-ve group (P < 0.05). On the
other hand, there was no significant difference between
IL-8 mRNA expression in CRC versus adenoma patients (P
> 0.05) (Table 4). In the non-tumorous tissue sections, it
was found that the positive expression of IL-8 mRNA was
not higher in CRC-Sg+ve group than in CRC-Sg-ve group
The percentage of seropositives for S. gallolyticus IgG anti-bodies in CRC, adenoma, and HV groups dependin  on the cutoff value calculat d fr m the tum r-free co trol groupFigur  2
The percentage of seropositives for S. gallolyticus IgG 
antibodies in CRC, adenoma, and HV groups depend-
ing on the cutoff value calculated from the tumor-
free control group. Colorectal adenoma and CRC groups 
showed high percentage of S. gallolyticus IgG seropositives 
while HV group showed much lower percentage.
Examples for NF-κB mRNA expression in the tumorous sec-tions of CRC patientsFigure 3
Examples for NF-κB mRNA expression in the tumor-
ous sections of CRC patients. (A) positive tissue section, 
>50% stained cells, and (B) tissue section, 5%-25% stained 
cells with stained stromal cells. Examples for IL-8 mRNA 
expression in CRC patients at (C) score 2, 11%-50% stained 
cells and at (D) score 1, 1%-10% stained cells. Cells stained 
positive are shown with dark color of NBT/BCIP in the 
nuclei of glandular cells (adenocarcinoma cells) (×400) and 
pointed by black bold arrow.Page 6 of 12
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0.05) (Table 4). This indicated that IL-8, unlike NF-κB,
was not much associated with the transformation process
of adenoma to CRC but, like NF-κB, was significantly
associated with S. gallolyticus in CRC patients.
By means of Pearson's correlation, it was shown that the
higher the level of S. gallolyticus IgG antibodies repre-
sented by ELISA readings, the higher the expression of IL-
8 mRNA in the tumorous tissue sections of CRC patients;
the correlation was significant and positive (r = +0.32, P <
0.05). Moreover, higher expression of IL-8 mRNA in CRC
was associated with more advanced stages of CRC (P <
0.05) but not with tumor grade (P > 0.05), in that CRC
patients who showed high IL-8 mRNA expression (scores
Table 1: The expression of NF-κB mRNA in the tumorous and the non-tumorous tissue sections of CRC and adenoma patients as well 
as in normal tissue sections of control subjects.
Tissue sections of NF-κB Positive NF-κB mRNA 
expression N (%)
χ2 test
P value
Mean % of NFKB-positively 
stained cells
P value for positively stained 
cells
CRC:
Tumorous 36/50 (72) 0.0006 74.7 ± 4.7 <0.01
Non-tumorous 19/50 (38) 36.23 ± 3.6
Tumorous 36/50 (72) <0.0001 74.7 ± 4.7 <0.01
Normal tissue 4/30 (13.3) 21.8 ± 2.3
Non-tumorous 19/50 (38) 0.018 36.23 ± 3.6 <0.01
Normal tissue 4/30 (13.3) 21.8 ± 2.3
Adenoma:
Tumorous 7/14 (50) 0.04 57.73 ± 5.6 <0.01
Non-tumorous 2/14 (14.2) 27.85 ± 5.8
Tumorous 7/14 (50) 0.009 57.73 ± 5.6 <0.01
Normal tissue 4/30 (13.3) 21.8 ± 2.3
Non-tumorous 2/14 (14.2) 0.9 27.85 ± 5.8 >0.05
Normal tissue 4/30 (13.3) 21.8 ± 2.3
Table 2: The expression of IL-8 mRNA in the tumorous and the non-tumorous tissue sections of CRC and adenoma patients as well as 
in normal tissue sections of control subjects.
Tissue sections of IL-8 Median score of IL-8 
mRNA expression
P value for Mann-
Whitney of ordinal 
scores
Mean percentage of IL-8 
mRNA positively stained 
cells (%)
P value for positively 
stained cells
CRC:
Tumorous Score 2 0.018 26.6 ± 2.05 <0.01
Non-tumorous Score 1 9.28 ± 1.3
Tumorous Score 2 0.018 26.6 ± 2.05 <0.01
Normal tissue Score 1 7.3 ± 1.44
Non-tumorous Score 1 0.56 9.28 ± 1.3 >0.05
Normal tissue Score 1 7.3 ± 1.44
Adenoma:
Tumorous Score 2 0.018 23.71 ± 1.86 <0.01
Non-tumorous Score 1 7.92 ± 1.73
Tumorous Score 2 0.018 23.71 ± 1.86 <0.01
Normal tissue Score 1 7.3 ± 1.44
Non-tumorous Score 1 0.56 7.92 ± 1.73 >0.05
Normal tissue Score 1 7.3 ± 1.44Page 7 of 12
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and 24/30 (80%) of stage D.
It is noteworthy to mention that the level of expression of
tumor suppressor proteins p21, p27 and p53 which were
examined previously on the same samples by Immuno-
histochemistry assay, [unpublished data] showed no asso-
ciation with the seropositivity of S. gallolyticus in CRC
patients.
ISH immunostaining of stromal cells
IL-8 and NF-κB mRNA immunostaining of stromal cells
rather than glandular mucosal cells (adeno cells) showed
much lower levels than that of glandular mucosal cells in
both tumorous and non-tumorous tissue sections of CRC
Table 3: The expression of NF-κB mRNA in the tumorous and non-tumorous tissue sections of CRC versus adenoma patients and in 
CRC-Sg+ve versus CRC-Sg-ve groups.
tissue sections Positive NF-κB mRNA 
expression
N (%)
χ2 test
P value
Mean % of NFKB-positively 
stained cells
P value for positively stained 
cells
Tumorous tissue sections
Patients:
CRC 36/50 (72) 0.042 74.7 ± 4.7 <0.01
Adenoma 7/14 (50) 57.73 ± 5.6
S. gallolyticus seropositivity
CRC-Sg+ve 28/34 (82) 0.017 79.45 ± 6.2 <0.05
CRC-Sg-ve 8/16 (50) 64.6 ± 4.6
Non-tumorous tissue sections
Patients:
CRC 19/50 (38) 0.09 36.23 ± 3.6 >0.05
Adenoma 2/14 (14.2) 27.85 ± 5.8
S. gallolyticus seropositivity
CRC-Sg+ve 17/34 (50) 0.01 40.25 ± 3.7 <0.05
CRC-Sg-ve 2/16 (12.5) 27.7 ± 4.2
Table 4: The expression of IL-8 mRNA in the tumorous and non-tumorous tissue sections of CRC versus adenoma patients, and in 
CRC-Sg+ve versus CRC-Sg-ve groups.
Tissue sections Median score of IL-8 
mRNA expression
Mann-Whitney for
median scores
(P value)
Mean percentage of IL-8 
mRNA positively stained 
cells
(%)
student t test for posi-
tively stained cells
(P value)
Tumorous tissue sections
Patients:
CRC Score 2 0.64 26.6 ± 2.05 >0.05
Adenoma Score 2 23.7 ± 1.86
S. gallolyticus 
seropositivity:
CRC-Sg+ve Score 2 0.049 31.58 ± 4.2 <0.01
CRC-Sg-ve Score 1.5 16 ± 2.8
Non-tumorous tissue sections
Patients:
CRC Score 1 0.56 9.28 ± 1.3 >0.05
Adenoma Score 1 7.92 ± 1.73
S. gallolyticus
seropositivity:
CRC-Sg+ve Score 1 0.56 10 ± 2.9 >0.05
CRC-Sg-ve Score 1 7.56 ± 1.7Page 8 of 12
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expression of IL-8 and NF-κB in stromal cells of CRC but
not of adenoma patients was borderline higher in tumor-
ous than both normal and non-tumorous tissue sections
(P < 0.05). However, there was no difference between
non-tumorous and normal tissue sections in both CRC
and adenoma patients (P > 0.05) (Table 5). IL-8 mRNA
and NF-κB mRNA expression in stromal cells of both
tumorous and non-tumorous tissue sections was not dif-
ferent between CRC and adenoma patients and between
CRC-Sg+ve and CRC-Sg-ve groups (P > 0.05) (Table 5).
This indicated that mRNA expression of IL-8 and NF-κB in
stromal cells, like glandular cells, showed association with
CRC tumorous cells in comparison with non-tumorous
and normal cells, however, unlike glandular cells, it
showed no association with adenoma, the transformation
process from adenoma to CRC, and no association with
the seropositivity of S. gallolyticus IgG antibodies. This
might be attributed to the fact that the involved CRC cases
in this study were all of adenocarcinoma type.
Discussion
There are several microbial candidates, other than S. gallo-
lyticus, for the association with CRC such as S. pasterianus,
S. infantarius, S. salivarius, H. pylori, and some strains of E.
coli [2,3,7,9,17]. However, except for H. pylori, the associ-
ation of these bacteria has not been found as obvious as S.
gallolyticus. Nevertheless, few studies have been conducted
to investigate the serological aspect of S. bovis association
with colorectal carcinoma and adenoma and no study has
been conducted to investigate the serological association
of S. gallolyticus with colorectal carcinoma and adenoma.
The design of ELISA of the current study took into account
the feasibility of measuring IgG antibodies towards S. gal-
lolyticus and B. fragilis rather than IgM due to the expected
long period of exposure to these bacteria, if any. It was
previously shown that titers of IgM antibodies of S. bovis
biotype I in CRC patients lack the consistency because the
immune stimulation of CRC patients towards S. bovis has
occurred over a long period of time [26].
In this study, the level of S. gallolyticus IgG antibodies was
significantly higher in CRC and adenoma patients than in
control and HV groups. Darjee and Gibb stated that
patients with colonic cancer had higher median IgG anti-
body titers to S. bovis and E. faecalis preparations than con-
trol samples did [27]. Hence, the seroprevalence of IgG
antibodies against S. gallolyticus subspecies S. gallolyticus,
measured in the current study, showed the same behavior
of the seroprevalence of IgG antibody against S. bovis
NCTC 8133 (now is termed S. infantiarus). Moreover, the
findings of the study of Devriese et al support our find-
ings. They stated that S. gallolyticus is more likely to be
involved in human infections which and associated with
colonic cancer [8].
The association of seroprevalence of S. gallolyticus with
CRC and colorectal adenoma in this study was specific
because of the lack of similar seroprevalence association
of the other studied bacteria, namely B. fragilis. B. fragilis
was selected as one of the best candidate indicators for
monitoring any history of breach of the mucosal barrier
between large intestine and blood circulation by ulcera-
tion, tumor lesions, surgery, or necrosis. This draws our
attention on how S. gallolyticus could be associated with
CRC and adenoma. Is this association just a consequence
of the tumor lesion or this bacterium might act as tumor
initiator or promoter. Wanke and Bistrian revealed that
local actions of cytokines or of chemical mediators able to
promote vasodilatation and the enhancement of capillary
permeability, may support bacterial entry at the tumor
site, and increase bacterial adherence to various cells [28].
If this scenario was the explanation for the higher sero-
prevalence of S. gallolyticus in CRC and adenoma patients
than in HV and control groups, we should have seen the
same association for B. fragilis which is by far more dom-
inant than S. gallolyticus in the bowel and of 100% inci-
dence.
In addition, the association of S. gallolyticus with adenom-
atous polyps was another clue supporting the hypothesis
Table 5: The expression of NF-κB and IL-8 mRNA in the stromal cells of the tumorous and non-tumorous tissue sections of CRC, 
adenoma, CRC-Sg+ve, and CRC-Sg-ve groups.
Tissue section Mean percentage of NF-κB mRNA expression
%
Mean percentage of IL-8 mRNA expression
%
Normal tissue 21.8 ± 2.3 7.3 ± 1.44
Tumorous CRC 29.92 ± 3.5 11.55 ± 1.07
Non-tumorous CRC 23.2 ± 2.8 7.1 ± 1.3
Tumorous adenoma 24.15 ± 2.7 9.5 ± 1.37
Non- tumorous adenoma 23.06 ± 1.6 8.4 ± 1.1
Tumorous CRC-Sg+ve 30.41 ± 2.3 12.36 ± 1.72
Ttumorous CRC-Sg-ve 28.88 ± 1.85 9.84 ± 1.25
Non-tumorous CRC-Sg+ve 22.5 ± 1.74 7.2 ± 1.21
Non-tumorous CRC-Sg-ve 24.7 ± 1.52 6.8 ± 0.62Page 9 of 12
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of colorectal mucosa from early adenomatous polyp
stages to late CRC stages, taken into account that 90% of
preinvasive neoplastic lesions of the colorectum are pol-
yps or polyp precursors (aberrant crypt foci) [29]. The
findings of this study were in agreement with other stud-
ies like Fagundes et al. who revealed that this bacterium
among patients with septicemia and/or endocarditis is
also related, in a significant way, to the presence of villous
or tubulovillous adenomas in the large intestine [6].
Therefore, the serological investigation of S. gallolyticus in
this study has shown 4 factors of reliability; the statistical
significance of S. gallolyticus association with both adeno-
mas and CRC, no similar association was seen by the indi-
cator bacteria B. fragilis, relying on the measurement of
IgG rather than IgM antibodies which reflects better the
status of longstanding immune reaction against bacterial
antigens, and the agreement of our results with other stud-
ies that based on isolating S. gallolyticus from blood at the
bacteremic phase.
A colonoscopically proven control group was involved in
order to obtain punch biopsies of normal mucosal tissues
and also to calculate precisely the cutoff value of normal
seropositivity of S. gallolyticus IgG antibodies. After apply-
ing this cutoff value on HV, CRC, and adenoma groups, it
was apparent that such cutoff value can be used to screen
the high risk groups of the population at sensitivity ranges
from 68 to 78% for CRC and adenoma and at specificity
of 83.33%. Therefore, this assay can be used in designing
an optimized kit for screening and/or detecting CRC or
colorectal adenoma in the population by using simple,
cheap and noninvasive procedure. Four seropositive sub-
jects in HV group were examined by colonoscopy, 3 were
normal and 1 revealed a medium-sized non-malignant
hyperplasic polyp. The detected hyperplasic polyp might
be an earlier event than adenoma for the association of S.
gallolyticus with transformation of colonic mucosa. How-
ever, this needs a prospective study on an extensive popu-
lation to determine on solid basis the association extent of
benign polyps with S. gallolyticus.
The mRNA expression of NF-κB and IL-8 was significantly
higher in tumor cells than in histologically normal adja-
cent cells in both CRC and adenoma patients and it was
higher in CRC and adenoma than in control subjects. This
provided evidence that NF-κB and IL-8 might have a
remarkable role in the transformation of colorectal ade-
noma and CRC. Several steps were dedicated to explore
the nature of the association of NF-κB and IL-8 with color-
ectal adenoma and CRC in terms of relationship with S.
gallolyticus. It was found that the expression of NF-κB
mRNA in CRC-Sg+ve was significantly higher than in
CRC-Sg-ve patients in both tumorous and non-tumorous
tissue sections, and was higher in CRC than in adenoma
patients in tumorous rather than non-tumorous tissue
sections. These results were of high value by the virtue of
many reasons. First, to the best of our knowledge, no pre-
vious reports were found to elucidate any possible rela-
tionship between NF-κB and S. gallolyticus in CRC and
adenoma patients. Second, these findings pinpoint to a
possibility that NF-κB could be an essential factor for the
carcinogenic effect of S. gallolyticus on colorectal mucosa.
NF-κB is implicated in the transcription of many target
genes that exert carcinogenic role and many studies
revealed that the elevation of NF-κB activity was evident
in a number of human cancers, including breast cancer
[30], thyroid cancer [31], melanoma [32], and colon can-
cer [33,34]. Third, NF-κB mRNA expression was signifi-
cantly higher in CRC than in adenoma patients indicating
that NF-κB might play an important role in the transfor-
mation sequel from normal mucosa, to adenoma, and to
malignant CRC stage, where NF-κB expression was high-
est.
The probable mechanism of carcinogenesis by S. gallolyti-
cus via NF-κB is believed to be driven by the downstream
mediators of NF-κB. It was revealed that the synthesis of
many cytokines and active compounds, which are tran-
scriptionally dependent on NF-κB, is in response to S.
bovis and leads to the formation of COX-2, nitric oxide,
and free radicals such as superoxide [35], peroxynitrites,
and hydroxyl radicals [36], which all possess a highly
potent mutagenicity. Furthermore, S. bovis was proved
experimentally to induce ras oncogene [3] which requires
the cell survival function of NF-κB to overcome death sig-
nal initiated in transformed cells [37]. Therefore, like S.
bovis, it is possible that S. gallolyticus uses NF-κB as a sur-
vival tool against death signals along with its potentially
mutagenic downstream mediators.
Regarding IL-8, its mRNA expression in tumorous rather
than non-tumorous tissue sections of CRC-Sg+ve was sig-
nificantly higher than in CRC-Sg-ve patients. Neverthe-
less, IL-8 mRNA expression in both tumorous and non-
tumorous tissue sections of CRC was not higher than that
of adenoma patients. Pearson's correlation coefficient
revealed that the level of S. gallolyticus IgG antibodies was
positively correlated with IL-8 mRNA expression (r+0.32,
P = 0.022) indicating that S. gallolyticus seroprevalence
might be in parallel with IL-8 mRNA expression in CRC.
Furthermore, higher expression of IL-8 mRNA in CRC was
associated significantly with more advanced stages of
CRC. These findings highlighted several interpretations.
First, IL-8 is most probably associated with S. gallolyticus
and correlated well with its seroprevalence level which
might indicate a role to play for the association between
this bacterium and CRC. Second, unlike NF-κB, IL-8 asso-
ciation with S. gallolyticus was restricted to tumorous
rather than non-tumorous cells which might indicate aPage 10 of 12
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gallolyticus via IL-8. Third, in supporting the earlier analy-
sis, the level of IL-8 mRNA was not significantly different
between adenoma and CRC patients in both tumorous
and non-tumorous tissue sections while it was clearly
associated with disease progression and CRC staging.
The pattern of IL-8 mRNA expression led us to propose
that IL-8 is more likely a propagating factor for CRC and
lacks the promoting role in the transformation process
from colorectal adenoma to CRC. This might be attrib-
uted to the angiogenic role of IL-8 by which new blood
vessels are formed to meet the increasing demands of can-
cer growth. These findings are supported by Ellmerich et
al. who revealed that small amounts of IL-8 were detected
in the mucosa of control rats, while the level of IL-8 was
~4 to 3 folds higher in the mucosa of rats receiving S. bovis
and S. bovis wall extracted antigen fraction, respectively
[38]. On the other hand, because IL-8 transcription was
shown to be dependent on the cooperative action of two
transcription factors, NF-κB and AP-1 [39], hence, both
NF-κB and IL-8 might play an integrated role leading to a
series of steps to escape from death signals, release of
potentially mutagenic products, and preparing the needed
blood supply to the cancerous cells. Regarding the ISH
staining of stromal cells, they were found to express
mRNA of NF-κB and IL-8 much lower than that of glandu-
lar mucosal cells. Although mRNA expression of NF-κB
and IL-8 was not associated in stromal cells with S. gallo-
lyticus IgG antibodies, the NF-κB and IL-8 expression was
higher in tumorous CRC than in tumorous adenoma sec-
tions. Accordingly, glandular rather than stromal cells
have shown to be mainly responsible for the expression of
NF-κB and IL-8 as well as glandular rather than stromal
cells seem to play the major role in the association of S.
gallolyticus with colonic mucosa.
Conclusion
Taken together, S. gallolyticus subspecies gallolyticus was
found serologically associated with both CRC and color-
ectal adenoma. The seroprevalence of S. gallolyticus IgG
antibodies appeared as a reliable indication for the associ-
ation of this bacterium with CRC and adenoma. Moreo-
ver, S. gallolyticus has shown a specific association with
CRC and colorectal adenoma when compared with the
more dominant intestinal bacteria, B. fragilis. This pro-
vided evidence for a possible important role of S. gallolyti-
cus in the carcinogenesis of CRC from pre-malignant
polyps. In addition, the seroprevalence of S. gallolyticus
has shown to be a good candidate for formulating a
screening assay for the early detection of both adenoma
and CRC cases in high risk groups. Regarding the possible
underlying mechanisms of such association, NF-κB and
IL-8 rather than other transformation factors p21, p27
and p53 [unpublished data] might highly act as important
mediators for the S. gallolyticus-associated carcinogenesis
of adenoma to carcinoma. Moreover, it was concluded
that NF-κB exerts most probably a promoting carcino-
genic effect and IL-8 exerts mainly a propagating effect on
colorectal mucosal cells. We recommend conducting fur-
ther studies to reveal the in vitro effect of S. gallolyticus on
colorectal mucosal cells in relation to factors such as COX-
2, Ras, apoptosis markers, PGE2, TNF-alpha, IL-1, and IL-
6. We also recommend conducting a prospective screen-
ing study on the high risk groups of the population using
the formulated ELISA kit to measure the seropositivity of
S. gallolyticus IgG antibodies and assess the reliability of
such screening assay when conducted on a large scale
sample of the population.
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